Sarepta Therapeutics, Inc.
Antisense-induced exon exclusion in type VII collagen

Abstract:

The present disclosure relates to antisense oligomers and related compositions and methods for increasing the expression of functional human type VII collagen and methods for treating dystrophic epidermolysis bullosa and related disorders and relates to inducing exclusion of exon 80 in human type VII collagen mRNA.